Friday, October 9, 2015: 10:30 AM-12:00 PM
Room: 6--CF

At the conclusion of this session, participants will be able to:
- discuss the clinical impact of emerging mechanisms of resistance to selected pathogens using real clinical cases
- examine the mechanistic basis for antibiotic choices in resistant bacterial and fungal pathogens
- assess the consequences of emerging resistance on patient outcome







C. Arias,
Pfizer:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Merck Sharp and Dohme:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Cubist:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Theravance:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Bayer:
Consultant
,
Consulting fee
See more of: Symposium